Oligometastatic non-small cell lung cancer: Current management.

ABSTRACT:

Background

In the past decade, major developments have improved the survival of patients with oligometastatic non-small cell lung cancer (NSCLC). About 20% - 50% of patients with NSCLC present with oligometastases at diagnosis. For this group of patients, it seems that an increase in survival would justify aggressive local therapies. The development of minimally invasive surgery and advanced radiotherapy techniques like stereotactic body radiation therapy (SBRT) makes local control possible for selected patients with metastatic NSCLC. The advantage of SBRT over surgery is that it is a non-invasive technique, with minimum side effects, and is more suitable for fragile and elderly patients, non-candidates for surgery, or patients who refuse surgery.

Aim

The purpose of this rev

SUBMITTER: Roman-Jobacho A 

PROVIDER: S-EPMC8259607 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature